Appointment of Walid S. Kamoun, PhD. MSc., Global Head of Servier R&D Oncology
Paris, April 27, 2022 – Servier, an independent global pharmaceutical company, announces the appointment of Walid S. Kamoun, PhD. MSc., as Global Head of R&D Oncology. His mission is to support the transformation of the Group’s R&D and thus contribute to making Servier a renowned and innovative player in the field of oncology. He reports directly to Claude Bertrand, Executive Vice President Research and Development of Servier group.
“We are very pleased to welcome Walid to Servier. His experience and leadership will be essential to develop our oncology R&D activities and accelerate innovation in this field. Walid will play a key role within the team in the deployment of our R&D strategy to achieve our goal of launching a new molecular entity every 3 years and bringing new therapeutic solutions to patients,” said Claude Bertrand.
With 20 years of international experience in the basic research and health sector, Walid led Takeda’s cell therapy and early translational oncology unit before joining Servier. He managed several cross-functional teams moving programs from discovery to early and late clinical development for Immuno-Oncology therapeutics and cell therapy programs. From 2011 to 2018, Walid worked at Merrimack Pharmaceuticals in Boston. He led the nanotherapeutics team and its dedicated portfolio from research to clinical development initiation. He contributed to the research supporting the approval of a novel treatment for pancreatic cancer.
“I am delighted to join Servier at a key moment when the Group is transforming. I am looking forward to collaborating with an international team of experts who work with and for patients to deliver innovations in the field of oncology,” said Walid S. Kamoun.
Walid S. Kamoun is a scientist with a strong medical background, he began his studies at the Faculty of Medicine in Tunis before becoming passionate about fundamental research and pursuing his career in the United States. He holds a Master of Science degree from the Computer Science department in Quantitative Image Analysis and a PhD in Vascular Biology from the University of North Carolina at Charlotte, USA, specializing in liver disease. He then pursued his research career at Massachusetts General Hospital / Harvard Medical School (Boston, USA). He contributed to numerous projects on tumor angiogenesis and more specifically in the study of the effects of anti-VEGF therapy on the tumor microenvironment in glioma and pancreatic cancer.